Compositions of microbiota and methods related thereto
View Patent ↗Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia , and Akkermansia . Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
1. A method of altering relative abundance of microbiota in a subject comprising administering to the subject an effective dose of a composition consisting essentially of substantially purified Verrucomicrobia; wherein the subject has a disorder selected from the group consisting of: obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, and abnormal lipid metabolism.
2. The method of claim 1 , wherein the substantially purified Verrucomicrobia is substantially purified Verrucomicrobiales.
3. The method of claim 2 , wherein upon administration of the substantially purified Verrucomicrobiales the relative abundance of Verrucomicrobiales is increased in the subject by at least about 5%.
4. The method of claim 1 , wherein the step of administering the composition comprises delivering the composition to at least a stomach, a small intestine, and a large intestine of the subject.
5. The method of claim 1 , wherein the substantially purified Verrucomicrobia is a live bacterial strain.
6. The method of claim 1 , further comprising administering an antibiotic and/or an osmotic laxative to the subject.
7. The method of claim 1 , wherein the relative abundance of Firmicutes, Tenericutes, or Erysipelotrichales is decreased at least about 5%.
8. The method of claim 1 , further comprising performing a surgical procedure selected from the group consisting of: gastric bypass, duodenojejunal bypass, biliopancreatic diversion, vertical sleeve gastrectomy, adjustable gastric banding, vertical banded gastroplasty, intragastric balloon therapy, gastric plication, Magenstrasse and Mill, small bowel transposition, biliary diversion, and duodenal endoluminal barrier.
9. The method of claim 1 , wherein the composition is administered orally.
10. The method of claim 1 , wherein the effective dose of the composition is administered before, concurrent with, or after a treatment with a composition or agent for bile acid modulation.
11. A method of treating obesity in a subject in need of the treatment, comprising administering a first effective dose of a composition comprising substantially purified Verrucomicrobia for increasing relative abundance of microbiota comprising Verrucomicrobia, Bacteroidetes, Proteobacteria and Firmicutes in a gastrointestinal tract of the subject in need thereof by at least about 5%.
12. The method of claim 11 , wherein the relative abundance of at least one of Verrucomicrobiales, Bacteroidales, Enterobacteriales, or Clostridia is increased by at least about 5%.
13. The method of claim 11 , wherein the relative abundance of at least one of Enterobacteriaceae, Rikenellaceae, Clostridiaceae, or Verrucomicrobiaceae is increased by at least about 5%.
14. The method of claim 11 , further comprising performing a surgical procedure selected from the group consisting of: gastric bypass, biliopancreatic diversion, vertical sleeve gastrectomy, adjustable gastric banding, vertical banded gastroplasty, intragastric balloon therapy, gastric plication, Magenstrasse and Mill, small bowel transposition, biliary diversion, and duodenal endoluminal barrier.
15. The method of claim 11 , further comprising administering an antibiotic to the subject.
16. The method of claim 11 , further comprising administering a compound to alter at least one of Bacteroidetes, Verrucomicrobia, Firmicutes, Tenericutes and Proteobacteria.
17. A method of altering microbiota in a subject comprising: administering an effective dose of a composition comprising substantially purified Verrucomicrobia to the subject, thereby altering abundance of one or more microbiota in the subject so that the microbiota mimics a microbiota found in a subject responsive to a gastric bypass or other gastrointestinal bariatric or metabolic procedure; wherein the subject has a disorder selected from obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, and abnormal lipid metabolism.
18. The method of claim 17 , wherein the composition alters at least one phylum or order selected from Bacteroidetes, Verrucomicrobia, Firmicutes, Tenericutes and Proteobacteria.
19. The method of claim 18 , wherein the administering the composition results in decrease of the relative abundance of at least one of Firmicutes, Tenericutes and Erysipelotrichales by at least about 5%.
20. The method of claim 17 , wherein the composition further comprises a compound that alters at least one of Bacteroidetes, Verrucomicrobia, Firmicutes, Tenericutes and Proteobacteria.
21. The method of claim 17 , wherein the effective dose of the composition is administered before, concurrent with, or after a treatment with a composition or agent for bile acid modulation.
22. A method of altering metabolic function in a subject, comprising administering an effective dose of a composition comprising substantially purified Verrucomicrobia, thereby
increasing the relative abundance of propionate-producing bacteria in a gastrointestinal tract of the subject by at least about 5%;
reducing acetate in a gastrointestinal tract of the subject; and
altering a ratio of short chain fatty acids in a gastrointestinal tract of the subject; wherein the metabolic function is increased.
23. The method of claim 22 , wherein the propionate-producing bacteria is Escherichia coli.
24. The method of claim 22 , wherein the ratio of short chain fatty acids is altered by manipulating bacteria in a gastrointestinal tract of the subject.
25. The method of claim 22 , wherein the ratio of short chain fatty acids is altered by creating and using bacteria to alter a ratio of short chain fatty acids in an environment.
26. The method of claim 22 , wherein the ratio of short chain fatty acids is altered by administering a cocktail of one or more short chain fatty acids to the subject.
27. The method of claim 22 , wherein metabolic function is determined by measuring body weight, food intake, or energy expenditure.
28. The method of claim 22 , wherein metabolic function is determined by measuring glucose metabolism, including insulin production or secretion, or insulin sensitivity.
29. The method of claim 22 , wherein the effective dose of the composition is administered before, concurrent with, or after a treatment with a composition or agent for bile acid modulation.